The 340B Rebate Model: What to Prepare Now

Under a rebate approach, a covered entity purchases an affected drug at wholesale acquisition cost, then submits claims data to receive the 340B discount back as a rebate — rather than receiving the discount automatically at the point of purchase. Operationally, that's a bigger shift than it sounds.

The cash-flow question comes first

The most immediate impact is working capital: money that used to arrive as a point-of-purchase discount is now tied up between purchase and rebate receipt. For high-volume purchasers of affected drugs, that gap is worth modeling before anything else.

Then the workflow question

A claims-submission workflow has to exist, be accurate, and handle disputes when a rebate claim is rejected or delayed. Programs that wait until go-live to build this tend to lose the first few submission cycles to process friction rather than policy disagreement.